Shamrock Technologies, Inc. v. Medical Sterilization, Inc. And Robert Luniewski

6 F.3d 788, 1993 U.S. App. LEXIS 38057, 1993 WL 366424
CourtCourt of Appeals for the Federal Circuit
DecidedSeptember 21, 1993
Docket93-1101
StatusUnpublished

This text of 6 F.3d 788 (Shamrock Technologies, Inc. v. Medical Sterilization, Inc. And Robert Luniewski) is published on Counsel Stack Legal Research, covering Court of Appeals for the Federal Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Shamrock Technologies, Inc. v. Medical Sterilization, Inc. And Robert Luniewski, 6 F.3d 788, 1993 U.S. App. LEXIS 38057, 1993 WL 366424 (Fed. Cir. 1993).

Opinion

6 F.3d 788

28 U.S.P.Q.2d 1693

NOTICE: Federal Circuit Local Rule 47.6(b) states that opinions and orders which are designated as not citable as precedent shall not be employed or cited as precedent. This does not preclude assertion of issues of claim preclusion, issue preclusion, judicial estoppel, law of the case or the like based on a decision of the Court rendered in a nonprecedential opinion or order.
SHAMROCK TECHNOLOGIES, INC. Plaintiff-Appellee,
v.
MEDICAL STERILIZATION, INC. and Robert Luniewski,
Defendants-Appellants.

No. 93-1101.

United States Court of Appeals, Federal Circuit.

Sept. 21, 1993.

Before ARCHER, RADER, and SCHALL, Circuit Judges.

RADER, Circuit Judge.

DECISION

The United States District Court for the Eastern District of New York awarded Shamrock Technologies, Inc. (Shamrock) damages for trade secret misappropriation and patent infringement by Medical Sterilization, Inc. and Mr. Luniewski (MSI). This court affirms.

BACKGROUND

This appeal arises from a bifurcated patent infringement action. This court previously affirmed partial summary judgment against MSI on the issues of patent validity and infringement. Shamrock Technologies, Inc. v. Medical Sterilization, Inc., 903 F.2d 789, 14 USPQ2d 1728 (Fed.Cir.1990) (Shamrock I ). Because Shamrock I discusses many facts of this case, this opinion may abbreviate its presentation.

For use in printing, polytetrafluoroethylene (PTFE) requires processing into a fine powder. Shamrock's patents recite a method for uniformly irradiating PTFE to reduce its molecular weight and facilitate this processing. Shamrock's United States Patent Nos. 4,748,005 ('005) and 4,777,192 ('192) cover this process. These patents issued on May 31, 1988 and October 11, 1988, respectively. Shamrock also owns United Kingdom Patent No. 2,119,385 ('385) published on December 18, 1985. The '005 patent duplicates the '385 patent. The patented process irradiates PTFE to break down long polymer chains. Breaking polymer chains facilitates grinding of PTFE into a fine powder.

Uniform irradiation is a key to processing PTFE. The prior art process carried the PTFE in trays on a conveyor belt past electron beam accelerators. This process did not irradiate the PTFE uniformly. Instead, top layers of PTFE received higher doses of radiation than bottom layers. The patented process stirs and agitates the PTFE during irradiation to ensure uniform exposure.

In 1975, Shamrock entered the irradiated PTFE market. Shamrock's PTFE processing business earned between $20 million and $22 million a year by the late 1980's. Due to excessive demand for its product, Shamrock even hired others, like Radiation Dynamics, Inc. (RDI), to supply some processed PTFE. RDI used the tray method of processing. In 1986, MSI supplied processed PTFE to Shamrock using the tray method.

During his employment at Shamrock from 1980 to 1983, Mr. Luniewski co-invented the patented process. When he became a Shamrock employee, Mr. Luniewski signed a written employment agreement to maintain the confidentiality of trade secret information. Mr. Luniewski assigned his patent rights to Shamrock. In 1983, Mr. Luniewski left Shamrock to work for MSI. Upon leaving Shamrock, Mr. Luniewski received $16,500.00 for signing another non-disclosure agreement.

Notwithstanding the nondisclosure agreement, Mr. Luniewski disclosed Shamrock's trade secret to MSI. This disclosure occurred before the '192 patent issued. MSI took advantage of the disclosure and sold over 360,000 lbs. of PTFE processed according to the patent. As mentioned above, this court has affirmed in Shamrock I the district court's holding that MSI infringed Shamrock's patents.

In the case at bar, the district court held that MSI misappropriated Shamrock's trade secret. The trial court awarded Shamrock $620,434.40 in lost profits and profits unjustly received by MSI due to the trade secret violation. MSI's profits sprang from sales to both Shamrock's customers and customers who had not dealt with Shamrock. In addition, the trial court awarded Shamrock $2,057,294.30 for patent infringement. This award encompasses lost profits from MSI's sales to Shamrock's customers and a reasonable royalty for MSI's sales to others. In summary, the total judgment against MSI is $2,677,728.70, plus interest on $2,057,294.30 at 1.5% above the prime rate from August 21, 1989.

DISCUSSION

Trade Secret Misappropriation

Federal district courts apply the trade secret law of the appropriate state. See Water Technologies Corp. v. Calco, Ltd., 850 F.2d 660, 670, 7 USPQ2d 1097, 1105 (Fed.Cir.1988); Syntex Ophthalmics, Inc. v. Novicky, 745 F.2d 1423, 1433 n. 21, 223 USPQ 695, 703 n. 21 (Fed.Cir.1984). In the case at bar, this court applies the trade secret law of the State of New Jersey.

To recover under New Jersey law for trade secret misappropriation, the plaintiff must show by a preponderance of the evidence: (1) the existence of a trade secret, (2) communicated to an employee having a duty of confidentiality, (3) disclosed by the employee in breach of that duty of confidentiality, (4) to a third party who knows of that breach of duty, (5) who uses the information to the detriment of the plaintiff. Adolph Gottscho, Inc. v. American Marking Corp., 18 N.J. 467, 474, 114 A.2d 438, 442, 105 USPQ 398, 402 (1955); Stone v. Goss, 65 N.J.Eq. 756, 55 A. 736 (1903). See also Rohm & Haas Co. v. Adco Chem. Co., 689 F.2d 424, 429-30, 215 USPQ 1081, 1085 (Fed.Cir.1982) (stating the elements of a misappropriation of trade secrets claim); Ferroline Corp. v. General Aniline & Film Corp., 207 F.2d 912, 921, 99 USPQ 240, 246 (7th Cir.1953). In addition, the plaintiff must show that he took "reasonable precautionary measures to maintain the secrecy" of the trade secret. Sun Dial Corp. v. Rideout, 16 N.J. 252, 260, 108 A.2d 442, 447 (1954).

The record shows that Shamrock established each of the elements for trade secret misappropriation by a preponderance of the evidence. First, the misappropriation occurred after issuance of the '005 patent and its duplicate the United Kingdom '385 patent. MSI's misappropriation used the "water injection" improvements of the '192 patent. At the time of the misappropriation, the '192 patent had not issued. The district court specifically found:

We further find that since the British patent did not disclose the improved procedure under the '192 patent, the use of that procedure violated Luniewski's obligation not to reveal it.

Shamrock Technologies, Inc. v. Medical Sterilization, Inc., 808 F.Supp. 932, 938, 25 USPQ2d 1692, 1697 (E.D.N.Y.1992). The art in the '192 patent was a trade secret before its issuance.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
6 F.3d 788, 1993 U.S. App. LEXIS 38057, 1993 WL 366424, Counsel Stack Legal Research, https://law.counselstack.com/opinion/shamrock-technologies-inc-v-medical-sterilization-inc-and-robert-cafc-1993.